Docetaxel, cisplatin, and fluorouracil with pegfilgrastim on day 3 as neoadjuvant chemotherapy for esophageal cancer.

ABSTRACT:

Purpose

A high risk of febrile neutropenia (FN) from neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for esophageal cancer has been reported. The optimal timing of prophylactic use of pegfilgrastim remains to be elucidated. To evaluate the effect of pegfilgrastim administered on day 3, we conducted a feasibility study.

Methods

Chemotherapy consisted of intravenous administration of docetaxel (70 mg/m² per day) and cisplatin (70 mg/m² per day) on day 1 and continuous infusion of 5-fluorouracil (750 mg/m² per day) on days 1-5. Pegfilgrastim was given as a single subcutaneous injection at a dose of 3.6 mg on day 3 during each treatment course. This regimen was repeated every 3 weeks for up to a maximum of three courses

SUBMITTER: Maeda O 

PROVIDER: S-EPMC10831909 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature